Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Food Protection docket

This article was originally published in The Tan Sheet

Executive Summary

FDA established a public docket to receive information and comments related to its Food Protection Plan, according to an April 2 Federal Register notice. The plan published in November calls for providing the agency with mandatory recall power (1"The Tan Sheet" Nov. 12, 2007, p. 6). The agency asks for comments on three elements: prevention, intervention and response. Some of the questions include, "What, if any, significant gaps are there in the key prevention steps and the associated FDA actions listed in the plan?" and "What are potential data sources other than FDA data to inform the risk-based approach?" The deadline for comments is July 31...

You may also be interested in...



Mandatory Food Recall Power For FDA Better Than Using Existing Authorities?

FDA needs funding to execute the enforcement authorities it already has, not the additional authority it is asking for to order mandatory recalls of food products, including dietary supplements and vitamins, industry stakeholders say

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.

Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings

Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel